中咽頭がんに対する定位ブーストおよび短期放射線療法 (SHORT-OPC)
HPV関連中咽頭がん試験に対する定位ブーストおよび短期コース放射線療法:無作為化多中心第II相試験
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
調査の概要
状態
詳細な説明
Concurrent platinum-based chemoradiation remains the standard of care in locally advanced head and neck cancer. The current standard radiation regimen consists in a 7-week course of conventionally fractionated radiotherapy to the gross tumor volume (GTV), along with bilateral prophylactic neck irradiation to an elective dose of ~ 50 Gy in 2 Gy per fraction. In addition to being cumbersome, the current protracted daily radiation course is associated with high rates of acute and late toxicities and significant deterioration of patients' quality of life. In the light of the remarkably improved prognosis of the distinct subgroup of HPV-OPC, there is growing interest for treatment de-intensification strategies in contemporaneous OPC cohorts.
Stereotactic ablative radiotherapy (SABR) allows for ultra-precise delivery of ablative radiation dose over a small number of fractions, by combining sharp dose gradients with use of optimal image guidance. The increased conformity and reduced margins used in SABR can substantially reduce the dose to surrounding organs at risk and could therefore reduce toxicity. In addition, previous work has shown that an elective dose of 40 Gy in 2 Gy per fraction, in conjunction with chemotherapy, is sufficient for microscopic sterilisation of cancer cells and can translate into a reduction of toxicities.
The goal of this trial is to compare the efficacy and safety of short-course chemoradiation consisting in stereotactic boost to the gross tumor of 14 Gy in 2 fractions followed by de-esclalated chemoradiation (40 Gy in 20 fractions and concurrent 2 cycles of Cisplatin 100mg/m2) in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation (70 Gy in 33 fractions with 2-3 cycles of Cisplatin 100mg/m2).
This is an open label randomized phase III non inferiority trial. Patients will be randomized using a 1:1 ratio between the standard and the experimental arm and will be stratified by tumor stage and use of concurrent chemotherapy.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Diane Trudel
- 電話番号:514-890-8254
- メール:diane.dt.chum@ssss.gouv.qc.ca
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- University of Texas MD Anderson Cancer Center
-
コンタクト:
- Troy Sneed
- 電話番号:(713) 794-5472
- メール:TSneed@mdanderson.org
-
主任研究者:
- Jack Phan, MD PhD
-
-
-
-
British Columbia
-
Kelowna、British Columbia、カナダ、V1Y 5L3
- 募集
- BC Cancer - Kelowna
-
コンタクト:
- Jennifer Petterson
- 電話番号:250-717-4272
- メール:jennifer.petterson@bccancer.bc.ca
-
-
Ontario
-
London、Ontario、カナダ
- 募集
- London Health Sciences Center
-
コンタクト:
- Karen Eddy
- 電話番号:(519) 685-8500
- メール:Karen.Eddy@lhsc.on.ca
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X 1R6
- 募集
- Centre Hospitalier de l'Université de Montréal
-
コンタクト:
- Mom Phat
- 電話番号:26906 514-890-8000
- メール:mom.phat.chum@ssss.gouv.qc.ca
-
主任研究者:
- Houda Bahig
-
副調査官:
- Phuc-Félix Nguyen-Tan
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years
- Ability to provide written informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.
- Positive for HPV by p16 immunohistochemistry (IHC) or HPV in-situ hybridization (ISH)
- Clinical stage T1-3, N1 M0 (Stage I-II) as per AJCC 8th edition.
- Primary tumor < 30 cc
- Planned for curative chemoradiation
- For females of child-bearing age, a negative pregnancy test
Exclusion Criteria:
- Clinical N3 classification, as per AJCC 8th edition
- Clinically overt extranodal extension (ENE). As per AJCC 8th edition, clinically overt ENE is defined as invasion of the skin, infiltration of musculature/fixation to adjacent structures on clinical examination, cranial nerve, brachial plexus, sympathetic trunk or phrenic nerve invasion with dysfunction).
- Previous irradiation of the head and neck region
- Previous surgery of the HNC region (except for incisional or excisional biopsies)
- Pregnancy or breastfeeding
- Connective tissue disease
- Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
- Non-Cisplatin concurrent chemotherapy
- Prior induction chemotherapy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:SABR boost and de-escalated chemoradiation
SABR boost of 14 Gy in 2 fractions to the GTV, immediately followed by de-escalated chemoradiation. De-escalated chemoradiation will consist in 40 Gy in 20 fractions with concurrent high dose Cisplatin (3-weekly, 100 mg/m2) for 2 cycles, aiming for a cumulative dose of 200 mg/m2. |
Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions |
|
アクティブコンパレータ:Standard chemoradiation
The standard arm will consist of conventionally radiation to a dose of 70 Gy in 33 fractions concurrently with high dose Cisplatin (3-weekly, 100 mg/m2) for 2-3 cycles, aiming for a cumulative dose of ≥ 200 mg/m2. |
Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression free survival
時間枠:2 years after the end of chemoradiation
|
Patient alive with no local, regional or distant recurrence at 2 years after the end of chemoradiation |
2 years after the end of chemoradiation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Subacute toxicity
時間枠:Between 2 and 6 months after the end of chemoradiation
|
Rate of grade ≥ 3 subacute toxicity |
Between 2 and 6 months after the end of chemoradiation
|
|
Acute toxicity
時間枠:Less than 2 months after the end of chemoradiation
|
Rate of grade ≥ 3 acute toxicity |
Less than 2 months after the end of chemoradiation
|
|
Late toxicity
時間枠:Between 6 months and 5-years after the end of chemoradiation
|
Rate of grade ≥ 3 late toxicity |
Between 6 months and 5-years after the end of chemoradiation
|
|
OS
時間枠:At 2- and 5-years after the end of chemoradiation
|
Overall survival |
At 2- and 5-years after the end of chemoradiation
|
|
locoregional control
時間枠:At 2- and 5-years after the end of chemoradiation
|
Patient alive with locoregional control |
At 2- and 5-years after the end of chemoradiation
|
|
Head and neck symptom burden
時間枠:At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
Patient-reported head and neck symptom burden as measured by the MD Anderson Symptom Inventory Head and Neck Cancer Module. The core and head and neck cancer specific symptoms are rated on a 0-10 scale to indicate the presence and severity of the symptoms. Lower scores represent better functioning and quality of life. |
At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
|
Dysphagia
時間枠:At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
Patient-reported dysphagia as measured by the MD Anderson Dysphagia Index. Overall score ranges from 0 to 100, with higher score representing better functioning and quality of life. |
At baseline, and 1-, 3-, 6-, 12- months post-treatment, and yearly from years 2-5 after the end of chemoradiation
|
|
Time from treatment start to return to work
時間枠:Measured in days and reported at 2-years post-treatment
|
Time from first day of treatment start to first day of return to work. |
Measured in days and reported at 2-years post-treatment
|
協力者と研究者
協力者
捜査官
- スタディチェア:Phuc-Felix Nguyen-Tan, MD、Centre hospitalier de l'Université de Montréal (CHUM)
- 主任研究者:Jack Phan, MD PhD、M.D. Anderson Cancer Center
- 主任研究者:Khalil Sultanem, MD、Montreal Jewish General Hospital
- スタディチェア:Houda Bahig, MD PhD、Centre hospitalier de l'Université de Montréal (CHUM)
- 主任研究者:David Palma, MD PhD、London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。